Repligen (RGEN)

• Market cap: $7.7B
• 1 day: -1.66%
• 5 days: 0.37%
• 1 month: -12.41%
• 3 months: -5.79%
• 6 months: -6.04%
• Year to date: -4.15%
• 1 year: -25.78%
• 5 years: 48.16%
• 10 years: 348.54%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0.82% more ownership

Funds ownership: 99.49% [Q3] → 100.31% (+0.82%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

2% less capital invested

Capital invested by funds: $8.28B [Q3] → $8.09B (-$190M) [Q4]

4% less funds holding

Funds holding: 441 [Q3] → 425 (-16) [Q4]

12% less first-time investments, than exits

New positions opened: 57 | Existing positions closed: 65

15% less repeat investments, than reductions

Existing positions increased: 135 | Existing positions reduced: 158

47% less call options, than puts

Call options by funds: $40.1M | Put options by funds: $75.5M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $155 13% upside
• Avg. target: $182 33% upside
• High target: $205 50% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Evercore ISI Group Daniel Markowitz 0% 1-year accuracy 0 / 2 met price target	13% upside $155	In-Line Initiated	18 Mar 2025
RBC Capital Conor McNamara 8% 1-year accuracy 3 / 37 met price target	50% upside $205	Outperform Maintained	21 Feb 2025
JP Morgan Rachel Vatnsdal 50% 1-year accuracy 8 / 16 met price target	46% upside $200	Overweight Maintained	21 Feb 2025
HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 125 / 340 met price target	31% upside $180	Buy Reiterated	21 Feb 2025
Canaccord Genuity Kyle Mikson 37% 1-year accuracy 10 / 27 met price target	24% upside $170	Hold Maintained	21 Feb 2025